CompanyGraph
Guangdong Lifestrong Pharmaceutical Co., Ltd.
301111 · SZSE · China
wnqzy.com.cnFinancials as of FY2025
What stands out
- Pays more per share than it earned over the last twelve months
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Pays more per share than it earned over the last twelve months
Dividends view
Yield
0.22%
Annual Rate
CNY 0.05Paid unknown
Payout Ratio
142.5%High
Last Ex-Dividend
Jun 11, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.56BCNY531.22M · vs all stocks (USD)
Trailing P/E
556.25xRevenue (TTM)
304.63MCNY45.46M · vs all stocks (USD)
Profit Margin
1.94%Beta
0.9770xvs all stocks
52-Week Change
43.15%vs all stocks
Forward Annual Dividend Yield
0.22%vs all stocks
Market Capitalization
3.56BCNY531.22M · vs all stocks (USD)
Enterprise Value
3.09BCNY461.79M · vs all stocks (USD)
Trailing P/E
556.25xPrice to Sales (TTM)
11.69xPrice to Book (MRQ)
4.80xEnterprise to Revenue
10.16xGross Margin
61.13%Profit Margin
1.94%Operating Margin
5.96%Return on Assets (TTM)
-0.34%Return on Equity (TTM)
0.41%Revenue (TTM)
304.63MCNY45.46M · vs all stocks (USD)
Revenue per Share (TTM)
2.03CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-6.40%Gross Profit (TTM)
174.23MCNY26.00M · vs all stocks (USD)
EBITDA (TTM)
15.34MCNY2.29M · vs all stocks (USD)
Net Income (TTM)
5.93MCNY884.25K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-6.41%Operating Cash Flow (TTM)
17.10MCNY2.55M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.48MCNY220.78K · vs all stocks (USD)
Forward Annual Dividend Rate
0.0500CNYUpdated Sep 21, 2026Forward Annual Dividend Yield
0.22%vs all stocks
Trailing Annual Dividend Rate
0.0500CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.23%vs all stocks
Payout Ratio
142.45%Minority Interest (Equity)
531.22KCNYFY2025 · Dec 31, 2025Revenue
314.64MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
123.78MCNYFY2025 · Dec 31, 2025Gross Profit
190.86MCNYFY2025 · Dec 31, 2025Operating Income
-18.05MCNY-2.69M · vs all stocks (USD)
Pre-tax Income
-9.76MCNYFY2025 · Dec 31, 2025Income Tax Expense
-626.78KCNYFY2025 · Dec 31, 2025Net Income
-9.13MCNYFY2025 · Dec 31, 2025EBIT
-6.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
15.34MCNYFY2025 · Dec 31, 2025Research & Development
8.49MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
140.25MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.53MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.00MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.06MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0300CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
149.63MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
149.63MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-9.13MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.64MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-33.31MCNYFY2025 · Dec 31, 2025Free Cash Flow
-42.48MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
142.64MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-9.13MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.02MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-38.00MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
8.80MCNYFY2025 · Dec 31, 2025Capital Expenditures
-9.17MCNYFY2025 · Dec 31, 2025Net Acquisitions
13.08MCNYFY2025 · Dec 31, 2025Purchase of Investments
-378.05MCNYFY2025 · Dec 31, 2025Sale of Investments
352.46MCNYFY2025 · Dec 31, 2025Other Investing Activity
543.97KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-21.14MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.00MCNYFY2025 · Dec 31, 2025Other Financing Charges
2.11MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.89MCNYFY2025 · Dec 31, 2025Shares Outstanding
160.00MSharesUpdated Sep 21, 2026Float Shares
90.20MSharesUpdated Sep 21, 2026% Held by Insiders
46.69%vs all stocks
% Held by Institutions
6.53%vs all stocks
Total Cash (MRQ)
518.09MCNY77.31M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.24CNYUpdated Sep 21, 2026Total Debt (MRQ)
43.83MCNY6.54M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0581xCurrent Ratio (MRQ)
6.23xBook Value per Share (MRQ)
4.64CNYUpdated Sep 21, 2026Total Assets
894.13MCNY133.42M · vs all stocks (USD)
Total Current Assets
700.90MCNYFY2025 · Dec 31, 2025Total Liabilities
142.91MCNYFY2025 · Dec 31, 2025Total Non-current Assets
193.23MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
40.63MCNYFY2025 · Dec 31, 2025Total Current Liabilities
102.28MCNYFY2025 · Dec 31, 2025Cash
142.78MCNYFY2025 · Dec 31, 2025Cash Equivalents
351.95KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
143.14MCNYFY2025 · Dec 31, 2025Other Short-term Investments
77.59MCNYFY2025 · Dec 31, 2025Accounts Receivable
76.60MCNYFY2025 · Dec 31, 2025Inventory
77.31MCNYFY2025 · Dec 31, 2025Accounts Payable
63.72MCNYFY2025 · Dec 31, 2025Short-term Debt
5.24MCNYFY2025 · Dec 31, 2025Other Current Liabilities
868.67KCNYFY2025 · Dec 31, 2025Long-term Debt
40.24MCNYFY2025 · Dec 31, 2025Common Stock (Book)
160.00MCNYFY2025 · Dec 31, 2025Retained Earnings
149.68MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
751.22MCNY112.10M · vs all stocks (USD)
52-Week Low
15.08CNYUpdated Sep 21, 202652-Week High
31.36CNYUpdated Sep 21, 202652-Week Change
43.15%vs all stocks
Beta
0.9770xvs all stocks
50-Day MA
20.56CNYUpdated Sep 21, 2026200-Day MA
21.90CNYUpdated Sep 21, 2026Avg 10-Day Volume
5.09MSharesUpdated Sep 21, 2026Avg 30-Day Volume
6.94MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.0400CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 1.42Dividend per Share: 0.05Earnings per Share: 0.04
High gross margins eroded by operating costsNotable
Gross Margin: 0.61Profit Margin: 0.02
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eupraxia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
LivsMed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cerus Corporation
Tier 1ProductionApproval-Gated PipelineRule
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface